NCT03055962

Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese Subjects

A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Eisai Co., Ltd. · Industry
• Sex: All
• Age: 50 Years – 85 Years
• Healthy volunteers: Accepted

Summary

Study E2609-J081-014 is a single-center, randomized, double-blind, placebo-controlled study conducted to evaluate the safety and tolerability of multiple oral doses of E2609 50 milligrams (mg), administered once daily for 14 days, in healthy Japanese participants aged 50 to 85 years.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	E2609	tablet
DRUG	Placebo	tablet

Timeline

• Start date: 2017-02-14
• Primary completion: 2017-03-29
• Completion: 2017-04-11
• First posted: 2017-02-16
• Last updated: 2017-04-18

Locations

1 site across 1 country: Japan